Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned.
DISCUSSION: There is no convincing clinical evidence of chloroquine, hydroxychloroquine with or without azithromycin, and remdesivir use in COVID-19. As evidence of systemic inflammation is rapidly unfolding, there is a dire need to maximize our resources to find the best possible solutions to the current crisis while conclusive evidence from clinical trials emerges.
PMID: 32691699 [PubMed - as supplied by publisher]
Source: Vascular - Category: Surgery Authors: Sultan S, Acharya Y Tags: Vascular Source Type: research
More News: Azithromycin | Bleeding | Brain | Cardiology | Cardiovascular | Clinical Trials | Coronavirus | COVID-19 | Drugs & Pharmacology | Heart | Hydroxychloroquine | Lessons | Neurology | Respiratory Medicine | SARS | Stroke | Study | Surgery | Thrombosis | Zithromax